Mohamed Abdel Hady is Director, Affiliate Head of Patient Safety at Gilead Sciences, where he leads pharmacovigilance strategy, inspection readiness, and CAPA excellence across complex regulatory landscapes. He oversees RMP/PSUR programs and risk‑minimization measures and drives cross‑functional collaboration with affiliates and regulators across countries within Eurasia and Middle East.

In addition, Mohamed currently serves as Lead of the PHAME Group (Pharmacovigilance Association for Middle East), a regional industry forum. PHAME spans GCC, Levant, and North Africa, fostering regulatory intelligence sharing and collaborative problem‑solving.